Executive record

J. Kelly Ganjei

Director at Inmune Bio, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:j-kelly-ganjeiVersion: public-0As of: 2026-09-30

Not yet claimed10 published Claims4 sources
  • Director

Key Claims

Biography

Former CEO and President of AmplifyBio LLC and former CEO and Chairman of Cognate BioServices (acquired by Charles River Laboratories). Nearly 30 years of experience in life science, venture capital and IT sectors, including developing global informatics infrastructure at TissueGene.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Independent Director · Organization not publishedINMB DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. INMB DEF 14A director slate

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Chair · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Compensation, Nominating/Governance · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026

  2. INMB DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and machine learning experience reported in filings · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Inmune Bio, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Independent Director · Claim reviewed: May 16, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026

  3. Open source

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Inmune Bio, Inc. · Claim reviewed: May 16, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Inmune Bio, Inc. · Claim reviewed: May 16, 2026